Shots:
- Pfizer has entered into an exclusive global collaboration & license agreement with YaoPharma for YP05002, a GLP-1 receptor agonist for chronic weight management
- As per the deal, YaoPharma will complete the ongoing P-I trial of YP05002 & grant Pfizer exclusive global rights for further development, manufacturing & commercialization, receiving $150M upfront & ~$1.935B in milestones plus tiered royalties if the asset is approved
- Additionally, Pfizer is planning to test YP05002 in combination with its P-II GIPR antagonist PF-07976016 & other small-molecule candidates in its pipeline
Ref: Pfizer | Image: Pfizer & YaoPharma |Press Release
Related News: Metsera Announces an Amended Merger Agreement with Pfizer for ~$10B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
